Health News Archive - April 30, 2009
Two Phase 3 studies to start in the second half of this year BERLIN and TARRYTOWN, N.Y., April 30 /PRNewswire-FirstCall/ -- Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc.
A majority of U.S. women say the sagging economy has negatively affected their mental health, a survey indicates.
SANTA MONICA, Calif., April 30 /PRNewswire-FirstCall/ -- Cord Blood America, Inc.
LAUSANNE, Switzerland, April 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the field of oncology, announced that on April 7, 2009 the last patient was randomised to take part in a phase IIb clinical study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C (HCV) effect.
Digirad Reaches Quarterly Net Income POWAY, Calif., April 30 /PRNewswire-FirstCall/ -- Digirad Corporation (Nasdaq: DRAD), today reported it was ahead of internal schedules on its 2009 goal of generating consistent profitability and positive cash flow.
BOSTON, April 30 /PRNewswire-FirstCall/ -- Perceptive Informatics, the industry's leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced that it has developed a robust medical imaging methodology for Central Nervous System (CNS) clinical trials involving Alzheimer's disease.
Largest Study to Date Will Evaluate SilverHawk Plaque Excision System for Treatment of Lower Extremity Peripheral Arterial Disease PLYMOUTH, Minn., April 30 /PRNewswire/ -- ev3 Inc.
SCHAFFHAUSEN, Switzerland, April 30 /PRNewswire-FirstCall/ -- ($ millions, except per-share amounts) Q2 2009 Q2 2008 % Change ------- ------- -------- Revenue $4,150 $4,863 (15%) (Loss) / Income from Continuing Operations ($2,555) $272 - Diluted EPS from Continuing Operations ($5.40) $0.56 Special Items ($5.95) ($0.11) Income from Continuing Ops Before Special Items $261 $325 (20%) Diluted EPS from Continuing Ops Before Special Items $0.55 $0.67 (18%) Tyco International Ltd.
PRINCETON, N.J., April 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today its financial results for the quarter ended March 31, 2009. Medarex's net loss for the quarter ended March 31, 2009 was $48.6 million, or ($0.38) per share.
RANCHO CORDOVA, Calif., April 30 /PRNewswire-FirstCall/ -- ThermoGenesis Corp.